# Peter Kolchinsky
āļāļāļāļāļāļāļāļēāļŠāļāđāļĒāļāļāļāļīāļĒāļĄ
āļāļąāļāđāļāļāđāļĨāđāļ§:
Top podcast episodes featuring peter kolchinsky.
𧎠The Shelf Life of Innovation: CRISPR, Biotech Culture & Winning Teams | Johnny Hu (Part 2/4)
𧎠The Biotech Startups Podcast is powered by Excedrâhelping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.
As a TBSP listener, you can get exclusive perks through Excedrâs parâĶ
"Will The Virus Win?" with virologist Peter Kolchinsky
Peter Kolchinsky is a scientist and biotechnology investor, with a deep understanding of how viruses outsmart us. His company, RA Capital Management, builds and invests in biotech companies.
Hosted on Acast. See acast.com/privacy for more information.
Where's the Promise of Biotech? Featuring Peter Kolchinsky
In this episode of FEGâs Insight Bridge Podcast, Greg Dowling speaks with Peter Kolchinsky, Managing Partner at RA Capital. Together they delve into the drivers and details of todayâs biotech industry, how to foster innovation and why Peter is optimistic about biotechâs ability to address autoimmunâĶ
Best-of Edition: Peter Kolchinsky & John LaMattina on the IRA
In this âBest ofâ edition, host Duane Schulthess revisits two landmark conversations on the long-term impact of the Inflation Reduction Act (IRA) on the biopharmaceutical industry. First, Peter Kolchinsky (Managing Partner, RA Capital Management; Steering Committee Member, No Patient Left Behind), âĶ
Two leaders from the Harvard Biotech Club talk about their experience in the club, its new podcast, The Pulse, and an upcoming career fair on September 19th
Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have already been guests). Plus, the September 19th career fair that traditionally draws 1,000 attendees and so far already has 17 companâĶ
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outsidâĶ
Making Value Propositions Clearer with Peter Kolchinsky, PhD, Founder and Managing Partner, RA Capital Management
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with Peter Kolchinsky, PhD, Founder and Managing Partner of RA Capital Management, to discuss if the U.S. market-based approach to pricing novel prescription medicines could result in paying more than they are worth aâĶ
Live from Boston: Investor math versus industrial priority
Should investors embrace Chinaâs fast-moving, fast-growing biotech sector, or should there be barriers to protect and preserve an industry that the US has dominated for decades? Ginkgo Bioworks CEO Jason Kelly, RA Capital Management's Peter Kolchinsky, and MIT professor Fiona Murray debate all sideâĶ
Peter Kolchinsky, PhD: Ideas That Refuse to Die
In the latest episode of Precision Signals, Sean Khozin speaks with Peter Kolchinsky, founder and managing partner of RA Capital Management.
Peterâs perspective is shaped in part by his experience as the child of Soviet Jewish immigrants. His parents brought him a deep appreciation for education, hâĶ
āđāļāļĢāļ·āđāļāļāļĄāļ·āļāļāđāļāļŦāļēāļāļāļāđāļāļŠāļāđ
āļāļļāļāļŠāļēāļĄāļēāļĢāļāđāļāđāđāļ§āđāļāđāļāļāđāļāļāļāđāļĢāļēāđāļāļ·āđāļāļāđāļāļŦāļēāļāļāļāđāļāļŠāļāđāļāļāļ3,822,650āđāļĨāļ°āļāļāļāļāļāļ195,582,889āļāļēāļĄāļāļļāļāļāļĨ āļŠāļāļēāļāļāļĩāđ āļŦāļĢāļ·āļāļŦāļąāļ§āļāđāļ
āļāļēāļĢāļĨāļāļāļļāļāđāļāļāļ§āļēāļĄāļĢāļđāđāđāļŦāđāļāļĨāļāļāļāđāļāļāļāļĩāļāļĩāđāļŠāļļāļ āļāļąāļāļāļķāļāļāļąāļāļāļāļāđāļāļŠāļāđ
‐ Benjamin "Llamacorn" Franklin
āđāļāđāđāļ
āļāļāļāļāļļāļāļāļĩāđāļāđāļ§āļĒāļāļģāđāļŦāđāļāļēāļāļāđāļāļĄāļđāļĨāļāļāļāđāļāļŠāļāđāļĄāļĩāļāļ§āļēāļĄāļāļąāļāļŠāļĄāļąāļĒ
